McDermott Advises Softhale on Sale to Sino Biopharmaceutical
Munich, March 31, 2021 – McDermott Will & Emery advised Softhale N.V. on the sale of the company to Sino Biopharmaceutical Limited and its subsidiary, C-Lab International Limited. The purchase price amounts to US$110 million, and additional payments related to regulatory and commercial milestones. Amongst the sellers are Rhein Healthcare Investors that held a 60% majority stake in Softhale so far.
With the addition of Softhale, Sino Biopharmaceutical intends to provide a key strategic hub in Europe and expects that the company will become an important developer of innovative respiratory products for China and the global market.
Softhale is a privately held Belgium-based respiratory company focused on the development of pharmaceutical products with superior clinical performance based upon differentiated technology.
Sino Biopharmaceutical Limited and its subsidiaries are a leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain of pharmaceutical R&D platforms, intelligent production and strong sales systems.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.